NICE has recommended rozanolixizumab as the first treatment for some adults in England living with uncontrolled generalised myasthenia gravis, marking a new option for a rare condition that can cause muscle weakness, extreme tiredness and repeated hospital visits.
A new option for a difficult-to-control condition
The recommendation, published in final draft guidance on 29 April 2026, applies to adults who test positive for certain antibodies, called AChR or MuSK, and whose symptoms remain poorly controlled despite standard treatments, including steroids. NICE said the drug could help around 800 adults in England and will be available on the NHS straight away through interim funding from the Innovative Medicines Fund.
Generalised myasthenia gravis is a long-term autoimmune condition that can affect breathing, speech, swallowing, eyesight and movement. NICE said there is currently no cure, and symptoms can flare unpredictably, which often leads to repeated hospital use and major disruption to daily life. NICE announcement
How the treatment is expected to help patients
According to NICE, studies show that when rozanolixizumab is added to existing treatment, it can reduce the severity of symptoms and help people manage everyday activities more easily. The medicine is given as a short course of injections under the skin and can be supported by a homecare service, allowing many people to administer it at home.
NICE said the more convenient approach could reduce disruption to work and family life, ease pressure on carers and improve mental wellbeing for people who find hospital treatment stressful or difficult. It also said better symptom control may allow some patients to reduce long-term steroid use, which could lower the risk of side effects.
Commercial deal clears the way for NHS access
Helen Knight, director of medicines evaluation at NICE, said the recommendation marks an important step forward for people living with the condition when it remains uncontrolled on current treatment. NICE added that the final draft recommendation followed agreement on an improved commercial deal between NHS England and the company, and that final guidance is expected next month.
The move adds to a series of recent NICE decisions aimed at improving access to treatments for people with serious and complex conditions, while also offering care that is easier to deliver outside hospital settings. NICE news articles
For patients and families affected by uncontrolled myasthenia gravis, the decision offers a new targeted therapy that may improve symptoms, reduce treatment burden and support greater independence in everyday life.
